HeartSciences (HSCSW) Common Equity (2021 - 2026)

HeartSciences (HSCSW) has 6 years of Common Equity data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 48.44% year-over-year to $2.7 million; the trailing twelve-month figure through Jan 2026 stood at $2.7 million (up 48.44% YoY), and the FY2025 full-year result was $205171.0, down 97.2% from the prior year.
• Common Equity for Q1 2026 stood at $2.7 million, down from $4.2 million in the prior quarter.
• Across five years, Common Equity topped out at $8.6 million in Q1 2024 and bottomed at -$6.1 million in Q2 2022.
• The 5-year median for Common Equity is $1.8 million (2025), against an average of $1.7 million.
• The widest annual swing landed in 2023, when Common Equity plunged 252.37%; it then jumped 3447.59% in 2024.
• A 5-year view of Common Equity shows it stood at $1.1 million in 2022, then slumped by 252.37% to -$1.6 million in 2023, then jumped by 343.48% to $4.0 million in 2024, then gained by 4.13% to $4.2 million in 2025, then slumped by 36.59% to $2.7 million in 2026.
• The last three Common Equity figures came in at $2.7 million (Q1 2026), $4.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.

Peer Comparison